A. ROSSI, O. RINALDI - Vol. 9, September 2003, Issue 3
Testo Bibliografia Summary Indice
Efficienza clinica nel trattamento con antipsicotici atipici
nella schizofrenia
Clinical effectiveness and atypical antipsychotic treatment of schizophrenia
1 DeQuardo JR, Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res 1998;32:229-42.
2 Lebowitz BD, Rudorfer MV. Treatment research at the millennium: From efficacy to effectiveness. J Clin Psychopharmacol 1998;18:1.
3 Kane J. Progress defined: Short-term efficacy, long-term effectiveness. Int Clin Pharmacol 2001;16(Suppl 1):S1-S8.
4 Nasrallah HA, Smeltzer DJ. Contemporary diagnosis and management of the patient with schizophrenia. Newtown, PA: Handbooks in Health Care 2002.
5 Summerfelt WT, Meltzer HY. Efficacy vs effectiveness in psychiatric research. Psychiatr Serv 1998;49:834-5.
6 Dorland’s Illustrated Medical Dictionary. 28th ed. Philadelphia (PA): WB Saunders Company 1994.
7 Olfson M. Emerging methods in mental health outcomes research. J Pract Psychiatry Behav Health 1999;5:20-4.
8 Streiner DL. The 2 "Es" of research: Efficacy and effectiveness trials. Can J Psychiatry 2002;47:552-6.
9 Nasrallah HA. Beyond efficacy and symptom control: effectiveness as the best measure of antipsychotic drug therapy. Proceedings of the Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 5-9, 2001, pp. 300-1.
10 Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 1):9-26.
11 Committee for Evaluating Medical Technologies in Clinical Use, Division of Health Promotion and Disease Prevention. Assessing medical technologies. Washington (DC): National Academy Press 1985:71.
12 Fichtner CG, Luchins DJ, Malan RD. Real-world pharmacotherapy with novel antipsychotics. J Pract Psychiatry Behav Health 1999;5:37-43.
13 Lalonde P. Evaluating antipsychotic medications: predictos of clinical effectiveness. Report of an Expert Review Panel on Efficacy and Effectiveness. Can J Psychiatry 2003;48(Suppl 1):3s-12s.
14 Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976a:218-22.
15 American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association 2000.
16 Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale: Reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-9.
17 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
18 Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
19 Liberman RP, Kopelowicz A. Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002;14:256-72.
20 Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1990;47:1066-72.
21 Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996;14(Suppl 3):27S-33S.
22 Velligan DI, Mahurin RK, Diamond PL, Hazelton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Res 1997;25:21-31.
23 Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophrenia Bull 1999;25:173-82.
24 Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophrenia Bull 2000;26:119-36.
25 Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993;16:295-312.
26 Perlick D, Mattis S, Stastny P, Teresi J. Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatry Clin Neurosci 1992;4:428-34.
27 Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
28 Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998;155:1080-6.
29 Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: Problems, prospects, and strategies. Schizophr Bull 1999;25:257-74.
30 Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 2000a;188:518-24.
31 Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000b;157:1317-23.
32 Martinez-Aran A, Penades R, Vieta E, Colom F, Reinares M, Benabarre A, et al. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother Psychosom 2002;71:39-46.
33 McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45:175-84.
34 Schillerstrom JE. Executive control function in psychiatric and medical illness. J Psychiatric Practice 2002;8:160-9.
35 Jaeger J, Douglas E. Neuropsychological rehabilitation for persistent mental illness. Psychiatr Q 1992;63:71-94.
36 Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993;26:122-6.
37 Bryson G, Bell MD, Kaplan E, Greig T. The functional consequences of memory impairments on initial work performance in people with schizophrenia. J Nerv Ment Dis 1998;186:610-5.
38 Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
39 Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643-8.
40 Mauri MC, Bravin S, Fabiano L, Vanni S, Boscati L, Invernizzi G. Depressive symptoms and schizophrenia: A psychopharmacological approach. Encephale 1995;21:555-8.
41 Lancon C, Auquier P, Reine G, Bernard D, Addington D. Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 2001;47:135-40.
42 Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980;137:801-5.
43 Glazer W, Prusoff B, John K, Williams D. Depression and social adjustment among chronic schizophrenic outpatients. J Nerv Ment Dis 1981;169:712-7.
44 Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am 1986;9:193-206.
45 Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-80.
46 Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-8.
47 Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
48 Nasrallah HA, Mulvihill T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry 2001;13:215-27.
49 Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002;73:297-311.
50 Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(Suppl 1):83-96.
51 Docherty JP, Van Kammen DP, Siris SG, Marder SR. Stages of onset of schizophrenic psychosis. Am J Psychiatry 1978;135:420-6.
52 Arvinitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
53 Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
54 Heck AH, Haffmans PM, de Groot IW, Hoencamp E. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: A double-blind, multi-center trial. Schizophr Res 2000;46:87-105.
55 Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 2001;55:403-14.
56 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
57 Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(Suppl 1):83-96.
58 Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
59 Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
60 Koro CE, Fedder DO, L’Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
61 McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
62 Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62(Suppl 27):10-4.
63 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26.
64 Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(Suppl 27):27-34.
65 Meltzer HY. Putting metabolic side effects into perspective: Risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl 27):35-9.
66 Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62 (Suppl 23):30-8.
67 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.
68 Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502.
69 Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
70 Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
71 Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-9.
72 Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976b:534-7.
73 Adams SG, Jr, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560.
74 Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-97.
75 Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophren Bull 1994;20:297-310.
76 Dott SG, Weiden P, Hopwood P. An innovative approach to clinical communication in schizophrenia: The Approaches to Schizophrenia Communication Checklists. CNS Spectrums 2001;6:333-8.
77 Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Practical Psychiatry 2001;7:41-47 (for copies of the scales and a training guide see Journal of Practical Psychiatry 2001;7:64-72).
78 Bell MD, Lysaker PH, Milstein RM. Clinical benefits of paid work activity in schizophrenia. Schizophr Bull 1996;22:51-67.
79 Mueser KT, Becker DR, Torrey WC, Xie H, Bond GR, Drake RE, Dain BJ. Work and nonvocational domains of functioning in persons with severe mental illness: A longitudinal analysis. J Nerv Ment Dis 1997;185:419-26.
80 Polak P, Warner R. The economic life of seriously mentally ill people in the community. Psychiatr Serv 1996;47:270-4.
81 Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.
82 McGlashan TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14:515-42.
83 Meyer JM, Nasrallah HA, eds. Medical illness and schizophrenia. Washington, DC: American Psychiatric Press 2003.
84 Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
85 Koran LM, Sox HC Jr, Marton KI, Moltzen S, Sox CH, Kraemer HC, et al. Medical evaluation of psychiatric patients: I. Results in a state mental health system. Arch Gen Psychiatry 1989;46:733-40.
86 Weiden PJ. Managing unhealthy behaviors in schizophrenia. J Psychiatric Practice 2000;6:160-8.
87 Barker S, Barron N, McFarland BH. Multnomah Community Ability Scale: User’s Manual. Portland, OR: Western Mental Health Research Center, Oregon Health Sciences University 1993.
88 Lehman AF. A Quality of Life Interview for the chronically mentally ill. Eval Program Plann 1988;11:51-62.
89 Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-97.
90 Becker M, Diamond R, Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res 1993;2:239-51.
91 Fischer EP, Cuffel BJ, Owen RR. Schizophrenia Outcomes Module. Little Rock, AR: University of Arkansas for Medical Sciences 1996.
92 McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60(Suppl 19):5-11.
93 Lyu RR, McCombs JS, Johnstone BM, Muse DN. Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Financing Review 2001;23:83-99.
94 Wahlbeck K, Chine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a sistematic review and meta-analysis of randomized trias. Am J Psychiatry 1999;156:990-9.
95 Brar JS, Chengappa KN, Parepally H, Sandman AR, Kreinbrook SB, Sheth SA, et al. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann Clin Psychiatry 1997;92:227-34.
96 Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalissed people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 1995;167:760-4.
97 Buckman RW, Malan RD. Clozapine for refractory schizophrenia: the Illinois experience. Clin Psychiatry 1999;60(Suppl 1):18-22.
98 Novartis Pharmaceuticals. Clozaril product monograph Dorval (QC): Novartis Pharmaceuticals 2002.
99 Health Canada. Association of Clozaril (clozapine) with cardiovascula toxicity [letter]. Ottawa (ON): Healt Canada January 14, 2002.
100 Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weigth: a controlled study. Am J Psychiatry 1996;153:817-9.
101 Wirshing DA, Spelberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
102 Larach VW, Zamboni RT, Mancini HR, Gallardo RT. New strategies for older problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr Res 1997;28:231-46.
103 Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-34.
104 Malla Ak, Norman RM, Scholten DJ, Zirul S, Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001;62:179-84.
105 Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizphrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504.
106 Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. Am J Psychiatry 1995;34:1292-6.
107 Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-63.
108 Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001;62:282-9.
109 Owens DG. Extrapyramidal side effects and tollerability of risperidone: a review. J Clin Psychiatry 1994;55(Suppl):29-35.
110 Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gall G, et al. Weigth gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41:337-43.
111 Janssen-Ortho Pharmaceuticals. Risperdal product monograph. Toronto (ON): Janssen-Ortho Pharmaceuticals 2002.
112 Haddad PM, Helleweil JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001;15:293-5.
113 Goodnick PJ, Rodriguez R, Santana O. Antipsychotics: impact on prolactine levels. Expert Opin Pharmacother 2002;3:1381-91.
114 Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactine levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(Suppl 1):53-67.
115 Raja M. Risperidone-induced absence of ejaculation. Int Clin Pychopharmacol 1999;14:317-9.
116 Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone Outcomes Study of Effectivenes (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 1999;60(Suppl 3):42-7.
117 Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62(Suppl 2):28-34.
118 Littrell KH, Johnson CG, Hilligos NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61:912-5.
119 Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in treatment-refractory schizophrenia. J Clin Psychiatry 1997;58:469-73.
120 Lilly Pharmaceuticals. Zyprexa product monograph. Toronto (ON): Lilly Pharmaceuticals 2002.
121 Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl 23):5-12.
122 Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes durino olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2001;63(Suppl 12):1135-9.
123 Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz Carrasco P, et al. The safety of olanzapine compared with other antipsychotic drugs: result of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic study of olanzapine in schizophrenia. Clin Psychiatry 2000;61:335-43.
124 Hamilton SH, Edgell ET, Reviki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psycopharmacol 2000;15:245-55.
125 Sharma T. Quetiapine – efficacy in different domains. Eur Neuropsychopharmacol 2001;11(Suppl 4):S385-90.
126 Velligan DI, Newcomwr J, Pulz J, Csernasky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-48.
127 Tauscher-Wisniwski S, Kapur S, Papatheodorou G, Jones C, Daskalakis ZJ, Zipursky B. Quetiapine in first-episode schizophrenia: treatment effects. International Congress on Schizophrenia Research 2001(Abstract ):247.
128 Tauscher-Wisniwski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992-7.
129 Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, et al. Improvement in cognitive function in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 2002;43(Suppl):S45-9.
130 Grcevich S, Delong VY. A retrospective analysis of quetiapine in the treatment of psychosis in children and adolescents. Paper presented at the 2001 International Congress on Schizophrenia Research 2001.
131 Emsley RA, Raniwalla J, Barley PJ, Jones AM. A comparison of the effects of quetiapine (Seroquel) and Haloperidol in sachizophrenia patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31.
132 Kasper S, Rak IC. Mantenance of long-term efficacy and safety of quetiapine in schizophrenia. Poster presented at a meeting of the American Psychiatry Association; New Orleans (LA): May 2001.
133 Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) Study. Clin Ther 2001;23:1839-54.
134 Goldstein JM, Chengappa KR, Parepally H, Brar JS, Mullen J, Schilling A. A random-assignment, double-blind, clinical trial of once- versus twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder. Poster presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology; Waikoloa (HI): 9-13 December 2001.
135 Kasper S, Tauscher J, Heiden A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001;11(Suppl 4):S405-13.
136 Kasher S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2001;1:783-801.
137 Jeste DV, Blazer WM, Morgensten H, Pulz JA, Yeung PP. Low incidence of persistent tardive dyskinesia with quetiapine treatment of pstchotic disorders in the elderly. Poster presented at the 13th Annual Meeting of the American Association for Geriatric Psychiatry; Miami (FL): 12-15 March 2000.
138 Astra Zeneca Pharmaceuticals. Seroquel product monograph. Mississauga (ON): Astra Zeneca Pharmaceuticals 2002.
139 Culter AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;24:209-22.
140 Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
141 Hellewell JS, Kalali AH, Langham SJ, et al. Patients satisfaction and acceptability of long-term treatment with quetiapine. Int J Psych Clin Pract 1999;3:97-105.
142 Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
143 Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9. Comment in: Lancet 2003;362:404; author reply 404-5.
144 Geddes J, Harrison P, Freemantle N. New generation versus conventional antipsychotics [letter]. Lancet 2003;362:404; author reply 404-5. Comment on: Lancet. 2003;361:1581-9.